Skip to main content
SpringerLink
Log in

Amifostine has potential as a chemoprotectant in patients receiving antineoplastic therapy

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Spencer CM, Goa KL. Amifostine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995 Dec; 50(6): 1001–31

    Article  PubMed  CAS  Google Scholar 

  2. British National Formulary No. 30. London: The Pharmaceutical Press, 1995 Sep

  3. 1995 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1995

  4. Glover D, Grabelsky S, Fox K, et al. Clinical trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 1989; 16: 1201–4

    Article  PubMed  CAS  Google Scholar 

  5. Glick J, Kemp G, Rose P, et al. A randomized trial of cyclophosphamide and cisplatin ± WR-2721 in the treatment of advanced epithelial ovarian cancer [abstract 258]. Proc Am Soc Clin Oncol 1992; 11: 109

    Google Scholar 

  6. Glick J, Kemp G, Rose P. A randomized trial of cyclophosphamide and cisplatin ae amifostine in the treatment of advanced epithelial ovarian cancer. Presented at the Thirtieth Annual Meeting of the American Society of Clinical Oncology; 1994 May 14–17; Dallas, Texas

  7. Glick J, Kemp G, Rose P, et al. A randomized trial of cyclophosphamide and cisplatin ae amifostine in the treatment of advanced epithelial ovarian cancer [abstract 1485]. Proc Am Soc Clin Oncol 1994; 13: 432

    Google Scholar 

  8. Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988; 61: 2192–5

    CAS  Google Scholar 

  9. Budd GT, Ganapathi R, Bauer L, et al. Phase I study of WR-2721 and carboplatin. Eur J Cancer 1993; 29A: 1122–7

    Article  PubMed  CAS  Google Scholar 

  10. Liu T, Liu Y, He S, et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992; 69: 2820–5

    Article  PubMed  CAS  Google Scholar 

  11. Niibe H, Takahashi I, Mitsuhashi N, et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumor. Nippon Gan Chiryo Gakkai Shi 1985; 20: 984–93

    CAS  Google Scholar 

  12. Niibe H, Takahashi I, Miyaishi K, et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumor. Nippon Gan Chiryo Gakkai Shi 1985; 20: 994–1001

    CAS  Google Scholar 

  13. Coia L, Krigel R, Hanks G, et al. A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies. Int J Oncol Biol Phys 1992; 22: 791–4

    Article  CAS  Google Scholar 

  14. Turrisi AT, Glover DJ, Hurwitz S, et al. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino) ethylphosphorothioic acid]. Cancer Treat Rep 1986; 70: 1389–93

    PubMed  CAS  Google Scholar 

  15. US Bioscience Ethyol to be marketed in US by Alza via $35 mil. deal. FDC Reports — Pink Sheet — T&G 1995 Dec 18; 2–3

  16. Substitution of cisplatin with carboplatin leads to better tolerability. Drug Ther Perspect 1996 Apr 15; 7(7): 14–6

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amifostine has potential as a chemoprotectant in patients receiving antineoplastic therapy. Drugs Ther. Perspect 7, 1–5 (1996). https://doi.org/10.2165/00042310-199607080-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199607080-00001

Search

Navigation